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Abstract: Among the gynaecological malignancies, ovarian cancer is one of the neoplastic forms with the poorest prog-
nosis and with the bad overall and disease-free survival rates than other gynaecological cancers. Ovarian tumors can be 
classified on the basis of the cells of origin in epithelial, stromal and germ cell tumors. Epithelial ovarian tumors display 
great histological heterogeneity and can be further subdivided into benign, intermediate or borderline, and invasive tu-
mors. Several studies on ovarian tumors, have focused on the identification of both diagnostic and prognostic markers for 
applications in clinical practice. High-throughput technologies have accelerated the process of biomolecular study and ge-
nomic discovery; unfortunately, validity of these should be still demonstrated by extensive researches on sensibility and 
sensitivity of ovarian cancer novel biomarkers, determining whether gene profiling and proteomics could help differenti-
ate between patients with metastatic ovarian cancer and primary ovarian carcinomas, and their potential impact on man-
agement. Therefore, considerable interest lies in identifying molecular and protein biomarkers and indicators to guide 
treatment decisions and clinical follow up. In this review, the current state of knowledge about the genoproteomic and po-
tential clinical value of gene expression profiling in ovarian cancer and ovarian borderline tumors is discussed, focusing 
on three main areas: distinguishing normal ovarian tissue from ovarian cancers and borderline tumors, identifying differ-
ent genotypes of ovarian tissue and identifying proteins linked to cancer or tumor development. By these targets, authors 
focus on the use of novel molecules, developed on the proteomics and genomics researches, as potential protein biomark-
ers in the management of ovarian cancer or borderline tumor, overlooking on current state of the art and on future per-
spectives of researches. 
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INTRODUCTION 
  Ovarian cancer is the sixth most frequent female cancer 
worldwide, with 200,000 new cases diagnosed every year, 
and the most lethal of all gynaecological cancers. Given that 
ovarian cancer in 75% of cases is diagnosed in advanced 
stage, the disease has a fairly poor prognosis with an overall 
five-year survival of around 40%, ranging from 10% for pa-
tients with tumors with distant metastases to 80% for pa-
tients with localized tumors [1]. 
  Ovarian tumors can be classified on the basis of the cells 
of origin in epithelial, stromal and germ cell tumors. Epithe-
lial ovarian neoplasms display great histological heterogene-
ity and can be further subdivided into benign, intermediate or 
borderline and invasive tumors. Borderline ovarian tumors 
(BOTs) account for 10%-20% of ovarian epithelial tumors 
and are typically diagnosed before 40 years of age, raising  
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issues regarding the use of conservative surgery to preserve 
fertility [2]. 
  So, despite enormous progress in cancer research, this 
disease represents one of the principal causes of death 
worldwide; therefore, there is a need for the identification of 
molecules which can act as indicators of an early malignant 
process, when disease burden is localized. However, the pos-
sibility to use many of these molecules in the clinical prac-
tice remains, unfortunately, still elusive. 
  Evaluation and validation of biomarkers need rigorous 
procedures to ensure clinical validity.  
  The process follows different steps to assist researchers 
in developing biomarker, these phases include: preclinical 
exploratory studies, clinical assay and validation, retrospec-
tive longitudinal, prospective screening and cancer control [3].  
  In addition, genomic and proteomics technologies have 
increased the number of potential biomarker entering clinical 
development, hence the validation of these candidate bio-
markers require an integrated effort among government, aca-
demic and pharmaceutical groups to coordinate the activity 
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GENERALITY ON PROTEOGENOMICS IN OVAR-
IAN CANCERS 
  In the case of ovarian cancer specific subtypes, it is often 
reported the evidence that different histological subtypes of 
ovarian cancer can be distinguished by some microarray pro-
filing, and that these subtypes might be partly reflected by a 
different aetiology through the deregulation and activation of 
different pathways.  
  This neoplasm heterogeneity could also account for dif-
ferent ovarian tumor behaviours and it could be revealed by 
specific biomarkers; for this evidence, it is reported by 
authors that gene expression profiling could be a useful 
prognostic tool, predicting chemo sensitivity to the standard 
treatment combination of paclitaxel and platinum chemo-
therapy for advanced ovarian cancer, but more knowledge 
about chemo sensitivity could eventually lead to a more tai-
lored cancer therapy [3-5]. 
  The purpose of this study is to summarize current dates 
regarding the use of novel protein biomarkers, based on ge-
nomics and proteomics, in the diagnosis, prognosis and re-
sponse to therapy in ovarian cancer and in borderline ovarian 
tumors. Our attention will be focus not only on serum mark-
ers but also on intracellular proteins. Indeed, the expression 
of these proteins can reflect cellular and molecular mecha-
nisms that control onset and neoplastic progression. Proteins 
included in this group belong to different cellular pathways 
including cellular metabolism and signal transduction. Of 
particular interest, it is the role of signaling molecules that 
regulate interaction pathways between tumor cells and the 
microenvironment. 
OVARIAN TUMORS AND BORDERLINE OVARIAN 
TUMORS (BOTs): MARKERS ACTUALLY USED IN 
CLINIC PRACTICE 
  Widely asymptomatic at the moment of the diagnosis, 
more than 70% of the patients with ovarian cancer are al-
ready in an advanced disease state [5]. On the contrary, 
BOTs are more common in women of younger age, do not 
share a similar epidemiological risk profile than women with 
invasive disease and appear to have a distinct genetic and 
protein background respect to high grade tumors. 
  The serum CA125 in combination with transvaginal or 
transabdominal ultrasonography (US) have been helpful for 
clinicians in the diagnosis and monitoring of a suspicious 
ovarian formation, leading to their acceptance for clinical 
screening [6], since US is a non-invasive acceptable proce-
dure with a large diffusion in world women screening pro-
grams and without complications. 
  The CA125, identified in 1981, is the only serum mole-
cules significantly associated with ovarian cancer, but also in 
endometriosis, pelvic inflammatory disease and other condi-
tions. Normally, serum levels are less than 35 U/ml and are 
increased in about 90% of patients with advanced ovarian 
cancer (stage III-IV) but only in 50% of women with early 
stage disease. This protein belongs to the protein family of 
mucins, a high molecular weight protein that normally coats 
the epithelium [7,8]. In virtue of their localization, mucine 
proteins have extremely important functions in cellular 
physiology, like, for example, cellular adhesion. Alterations 
in their oligosaccharide structure have been noticed in differ-
ent cancer forms [9]. CA 125 is a useful marker for the as-
sessment of response to chemotherapy, predicting relapses 
and for discrimination between benign and malignant masses 
[10,11]. The development of an algorithm that calculates risk 
of ovarian cancer, based on serial CA125 values, has shown 
that 20% of ovarian cancers have little or no expression of 
CA125 and has pointed out the importance of additional se-
rum markers identification, as well as of new molecules ca-
pable of completing or replacing CA125 altogether, to facili-
tate earlier detection of ovarian cancer [12]. 
  US in combination with CA125 has also been suggested 
as a potential means for early detection of ovarian cancer 
[13]; others studies confirmed the efficacy of this combina-
tion for the screening of ovarian cancer, but a recent study 
from the American National Cancer Institute (NCI), shows 
that these two screening methods, alone or in combination, 
can also produce many false-positive test results, causing 
needless surgery [14]. 
  For this reason, evaluation of a cystic formation with US 
characteristic of benignity, should lead to a normal echo-
graphic follow-up [13-15]. However, additional studies per-
formed with US screening have not demonstrated adequate 
sensitivity and sensibility for an early diagnosis of ovarian 
cancer [16]. Hereby, in ovarian cancer types detecting, good 
results were obtained by the combination of CA125 with 
others serum markers; serum total inhibin levels are sensitive 
and specific markers of epithelial ovarian cancer in post-
menopausal women; the production of inhibin by the ovaries 
almost stops after the menopause, but it continues from ovar-
ian tumors. After menopause, circular inhibin levels are un-
detectable; on the other hand, they are elevated in women 
with ovarian cancer [17]. Inhibin is a glycoprotein that exists 
as a dimeric form of two subunits ( e A o B), to form 
inhibin A and inhibin B (A) e B (B); moreover, inhibin 
seems to be complementary to CA125 and both markers 
have a total 95% of sensitivity with 95% of specificity.  
  Studies are directed toward establishing whether there are 
cancer specific inhibin forms, which may be suitable during 
the reproductive years, when these proteins show substantial 
fluctuations that would seriously compromise a preoperative 
assessment of any ovarian cancer [18]. 
PROTEIN MARKERS IN OVARIAN CANCER 
 Mesothelin is a cell surface protein present on normal 
mesothelial cells lining the body cavities and it is highly ex-
pressed in several cancers, including ovarian cancers. 
  Using mice lacking the Mesothelin gene, researchers 
have developed a monoclonal antibody directed against the 
protein and an ELISA assay for detecting serum mesothelin 
levels.  
  Elevated proteins levels have been detected in patients 
with mesothelioma and ovarian cancer [19]. Moreover, pro-
tein levels increase from the earlier form to more advanced 
cancer forms [20].  
  Serum mesothelin may be a useful test to monitor treat-
ment response in mesothelin-expressing cancers, because 
after surgery there is a rapid decrease in mesothelin levels in 
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lating serum mesothelin with detailed clinical information, 
such as tumor stage, tumor bulk, and response to treatment, 
will also have to be done to determine if serum mesothelin 
has prognostic significance and also if it can be used as a 
biomarker to assess response to other therapies besides sur-
gery [19]. 
  Important results have been obtained even in prognosis 
and in monitoring response to therapy. Signal Transducer 
and Activator of Transcription 3 (STAT3) is a latent tran-
scription factor in several neoplastic diseases; it normally 
resides in the cytoplasm and can be activated thought phos-
phorylation by several cytokines, hormones and growth fac-
tor that play their roles using STAT3 activated pathway, 
regulating different biological responses, like cell develop-
ment, differentiation, proliferation, motility, and survival 
[21]. 
  Expression of phosphorylated STAT3 form is increased 
in primary ovarian cancer and its nuclear localization is as-
sociated with a poor prognosis; further studies are needed to 
elucidate the mechanism of activation of Stat3, its effects on 
downstream targets, and its role in the neoplastic transforma-
tion of epithelial ovarian cells [22]. 
 LPAAT- (of which we know six human isoforms) is an 
enzyme that catalyzes the acetylation of Lisophospahtitic 
Acid (LPA), generating phosphatidic acid (PA), acting as a 
second messenger in tumor cell regulation of both prolifera-
tive and survival pathways [23].  
  An increase of enzyme expression has been correlated to 
a poor prognosis and is associated with a minor survival 
[24]; in SK-OV-3 and IGROV1 cell lines, small interfering 
RNA (siRNA) was used to silence the expression of 
LPAAT- reducing ovarian cancer cell lines viability [25]. 
 LPAAT- is an intriguing prognostic tool for the identifi-
cation of high-risk epithelial ovarian cancer (EOC) and it 
should be a molecular target toward which to direct therapy, 
because of the adverse clinical outcome associated with 
LPAAT-b expression, even for early-stage ovarian tumors 
[26]. 
  Among prognostic factors in ovarian cancers there are 
many members of Human Kallikrein Family (hK), a serine-
protease protein. This family gene is organized in a big clus-
ter, located in 19q13.4 chromosome; different immunohisto-
chemistry studies have shown that hK8 could be considered 
a marker of positive prognosis in patients with ovarian can-
cer [27,28].  
  In addition to hK8, extensive correlative clinical data 
have linked the over expression of 11 other kallikreins to 
ovarian cancer patient prognosis [29]. Although most reports 
link high kallikrein expression with poor patient prognosis 
(e.g., kallikreins 4, 5, 6, 7, 10, and 15), several studies also 
recognize some kallikreins as favourable prognostic indica-
tors (e.g., kallikreins 9, 11, 13, and 14) [30].  
  These clinical findings seem to be contradictory but have 
been explained by authors considering that hKs and prote-
ases in general, have a dual role during tumor progression. 
 Pyruvate  Kinase  (PK) is a key enzyme in glycolysis; the 
isoenzyme M2-PK is shifted to a dimeric form in a variety of  
 
tumors. Since the dimeric form is over-expressed in tumor 
cells, it is called pyruvate kinase tumor M2 (Tu M2-PK) 
[31].  
  Tu M2-PK is present in body fluids also, most likely re-
leased from tumor cells by tumor necrosis and cell turnover. 
It has been previously shown for various tumors that Tu M2-
PK determination in the circulation provides excellent dis-
crimination between benign and malignant disease or may 
provide additional information regarding sensitivity to che-
motherapy [32-34]. 
  In a recent study of Ahmed and colleagues, it has been 
supposed a possible link between TuM2-PK plasmatic levels 
and malignancy of ovarian cancer, showing that its concen-
tration was significantly raised in ovarian cancer patients, 
particularly those with higher stage disease [35]. In another 
study, the same researchers have tried to determine the cut-
off values for TuM2-PK sensitivity and specificity for differ-
entiating between benign and malignant ovarian disease. The 
average M2-PK concentration in cancer patients was 52 
U/ml versus 27 U/ml in patients with benign conditions (p < 
0.001). At a cut-off value of 22 U/ml the sensitivity of M2-
PK for detecting cancer was 70% with a specificity of 65%. 
However the M2-PK role in clinical practice needs further 
evaluation [36]. 
 c-MET ( Mesenchymal epithelial transition factor) is a 
proto-oncogene that encodes for a tyrosine kinase membrane 
receptor [37].  
  The c-Met protein is expressed mostly in in mammalian 
tissues and plays an important role in different cellular proc-
ess; its ligand is the HGF (Hepatocyte Growth Factor), 
known also as Scatter Factor (SF) and c-MET over-
expression or inactivation is implicated in different tumoral 
disease [38]. Recently, Sawada and colleagues have analyzed 
c-MET role in ovarian cancer biology and its possible impli-
cation as a therapeutic target; so, it has been established the 
c-MET over-expression, especially in patients in higher stage 
disease [38].  
  That c-MET level could represent a potential prognostic 
marker for patient with higher stage EOC has already been 
shown by the studies of Ayhan et al. [39].  
 But  in  Sawada  et al. study, silencing of c-MET messen-
ger in SKOV-3ip1 cells, cause inhibition of cellular adhesion 
to different extra cellular matrix components and human 
primary mesothelial cells; in parallel a significative reduc-
tion of -integrin and -integrin, urokinase and matrix metal-
loproteinase (MMP)-2/MMP-9 activity has been observed.  
  In summary, this study shows that c-Met is highly ex-
pressed in a subset of ovarian cancer patients and that its 
inhibition can reduce adhesion, invasion, metastasis, and 
ultimately tumor burden. It is tempting to speculate that, 
after the optimal surgical debulking of a patient with ovarian 
cancer, consolidation therapy with a drug that targets metas-
tasis will delay the repopulation of the peritoneal cavity by 
ovarian cancer cells [38]. 
  Moreover, in 2003 Maggiora et al. have established a 
link between c-MET and RON, another member of Tyrosin-
kinase receptor gene family, whose mutation is related to 
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  It has been demonstrated that, in vitro, RON and MET 
receptors cross-talk, synergize in intracellular signaling, and 
cooperate in inducing morphogenic responses; the same are 
significantly co-expressed in 42% (P < 0.001), hypothesizing 
that their action might promote ovarian cancer progression 
[40]. 
  Even if many possible biomarkers are directly produced 
by tumoral cells, recent evidences drew our attention on tu-
mor microenvironment, not only as an important factor in 
carcinogenesis, but also as a source of new markers. In fact, 
tumoral environment is constituted by a different cellular 
type system, like macrophages, fibroblasts, endothelial cells, 
lymphocytes, that actively attend to the tumoral progression 
process, through production of different molecules, measur-
able in biological fluids [41]. 
 Matrix  Metalloproteinase  (MMP) are a group of calcium-
zinc dependent photolytic enzymes, capable of reducing 
many extra cellular matrix component; they can be produced 
by tumoral and stromal cells [42].  
  In stromal cells, high levels of MMP-2, MMP-9 e MT1-
MPP, a subgroup of no soluble enzymes, connected to cellu-
lar membrane, are linked to a poor prognosis in patients with 
EOC. Although the role of MMPs as therapeutic targets re-
mains to be further defined, it is possible that broad MMP 
inhibitors (for example, Col-3; ref. [52]) targeting both 
epithelial and stromal MMPs may be useful in controlling 
ovarian cancer vascularization and metastasis [43]. 
 EphA2 is a tyrosine-kinase receptor of 130Kda, belong-
ing to Eph family; EphA2 is over-expressed in many can-
cers, including ovarian cancer, in which its expression is 
related to more aggressive cancer behaviour [44].  
 Interestingly, the EphA2 gene is located on chromosome 
1p36.1, which  is not only a genetic “hot spot” in cancer 
[45,46], but also the second most common site of complex 
karyotypic abnormalities in ovarian cancer [47]. 
 Dohn  et al. [48] showed that EphA2 transcription is regu-
lated by p53, a tumor suppressor protein is frequently mu-
tated in ovarian cancer [49,50].  
  If further study will determine the role of p53 mutations 
in regulating EphA2 levels [49,50], EphA2 may be a thera-
peutic target to treat ovarian carcinoma patients who have 
p53 mutations [51].  
  In addition, Hendrix et al. and Hess et al. have shown 
that EphA2 may play a role in vasculogenic mimicry [52, 
53]. 
  Therefore, targeting EphA2 may have direct anti-tumor 
and ant vascular effects. EphA2 role in tumorigenesis seems 
to concern invasion and angiogenesis process; in fact, levels 
of this receptor in endothelial and tumoral cells are linked to 
a major density of micro vessels and to an high expression of 
MMP-9, MMP-2, MT1-MMP [54].  
  Therefore, EphA2 represents an important predictor of 
clinical outcome and may be a potential ant vascular thera-
peutic target. Lin Y.G. et al. recently demonstrated that tar-
geting EphA2 while concomitantly using conventional cyto-
toxic chemotherapy successfully decreased tumor growth in 
vivo at least in part by inducing tumor-associated endothelial 
cell apoptosis [55], supporting EphA2 as a therapeutic 
antiangiogenic target.  
 PDEF belong to ETS transcription factor family, charac-
terized by a conservative domain of 85 aa that bind DNA. 
They are nuclear factors that participate as effectors in Ras-
MAPK pathway.  
  The mechanisms through which they seem to play a role 
in tumorigenesis or in ovarian cancer progression are still 
unknown; these factors could alter EOC physiology, possibly 
in a way similar to that studied in mammalian cancer cell 
lines, where they significantly increase mobility and inva-
sively.  
  Expression of this transcription factor has been studied, 
at mRNA and proteic level: data obtained show that 70% of 
ovarian cancer over-expressed PDEF mRNA; on the other 
hand, only in 33% of higher stage disease over-expressed 
PDEF protein [56]. 
  Different evidences suggest a link between inflammatory 
process and cancer onset [57]. 
  Many molecules produced by inflammatory tumoral or 
associated cells, like fibroblasts, play the role of mediator 
between these two processes. Cytokines are a heterogeneous 
protein family of low molecular weight, produced by immu-
nitary cells, but also by tumoral cells, that can act as stimula-
tors or inhibitors of growth and tumor progression [58].  
  Interleukin 13 (IL-13) is another cytokine with anti-
inflammatory activity, produced by T cells, that plays an 
important role in many biological activities, including cancer 
onset. IL-13 acts linking to its membrane receptor (IL-13R), 
constituted by two strands, IL13Ra1 and IL13Ra2. An al-
tered expression of this cytokine has been observed in tu-
moral tissue, in respect to normal ovarian tissue [59].  
  High level of a2 chain has been revealed in 44 on 53 ma-
lign ovarian cancer samples (83%) [60]. 
  Consistent with preclinical and clinical activities of IL13 
cytotoxin in phase I/II clinical trials, Kioi et al. [60] showed 
that IL-13 cytotoxin mediates antitumor activity.  
  One of the characteristics of ovarian cancer is their in-
traperitoneal (IP) spread, leading to an advanced stage of the 
disease invading other organs. Thus, the IP route of admini-
stration of therapeutic agents seems to be an appropriate 
route for disseminated ovarian cancer therapy; therefore, 
Kioi et al. investigated the efficacy of IL- 13 cytotoxin ad-
ministrated IP using either a continuous infusion pump or 
bolus administration. By these routes of administration, IL-
13 cytotoxin mediated dramatic antitumor effects in very 
large established s.c. xenografted tumors [60] and therefore, 
IL-13 is a promising target for ovarian cancer therapy.  
  Higher levels of serum macrophage migration inhibitory 
factor (MIF) were found in ovarian cancer patients’ blood 
(sensibility of 77,8% and specificity of 53,3%) [61].  
  Moreover, studies about co culture of macrophages with 
cancer cell lines showed that MIF expression is induced in a 
JNKII and NF-kB-dependent manner and acts inducing 
macrophages MMP release, promoting tumoral cells inva-
sively [62]. 244    Current Genomics, 2009, Vol. 10, No. 4  Tinelli et al. 
  MIF is an inflammatory cytokine that plays an important 
role in regulating innate and adaptive immune responses. 
The potent proinflammatory effect of MIF may mediate 
some of the stimulatory effects of inflammation on cancer 
progression; so, understanding its role on the inflammatory 
process associated with tumor development may provide 
insight into the mechanism by which chronic inflammation 
predisposes individuals to ovarian cancer and may open new 
venues for targeted therapy [63].  
  Attempts to provide insight into mechanisms of action of 
MIF have suggested that the protein acts by stimulating in-
flammatory signals in the ascitic microenvironment such as 
IL-6, IL-10 and TNF- [62]. 
 NGAL (Neutrophil gelatinase-associated lipocalin) be-
longs to the lipocalin protein family. It is a protein stored in 
the specific granules of human neutrophils and works limit-
ing bacterial growth at sites of infection. Lipocalins have 
unusual expression in tumoral tissues, respect to normal ones. 
  The NGAL concentration was higher in the serum of 
patients with borderline grade 1 tumors respect to grade 2 
and grade 3 ones and to benign tumor. More studies are 
needed to further evaluate the role of NGAL in the progres-
sion of ovarian carcinoma and its potential targeting in diag-
nosis and treatment [64]. 
  Tumoral cells capacity to escape to immunity surveil-
lance was proposed as one of the cancer fundamental charac-
teristic, for the first time by Dann et al. [65]. One way used 
by cancer to escape from immunity system attach is the 
“immunosovvertion”, that is, the immunity system suppres-
sion, through superficial or soluble specific molecules ac-
tions.  
 CD46 is a membrane protein that protects cells against 
complement-mediated toxicity. An immunohistochemistry 
assay on 73 ovarian cancer biopsies showed that CD46 ex-
pression is linked to a poor prognosis [66]. 
  RCAS1 (Receptor-binding cancer antigen expressed on 
SiSo cells) is a protein that induces immunity cells-RCAS1 
receptor expressing apoptosis, like T cells and Natural Killer 
cells [67]. 
  By immuno-localization studies, an high RCAS1 expres-
sion was shown in breast, gallbladder and colorectal cancers 
[68,69]. Patients with uterine cancer showed higher serum 
levels, compared to control; moreover, RCAS1 levels are 
correlated to therapy response [70]. 
ROLE OF THE PROTEOMICS IN THE IDENTIFICA-
TION OF BIOMARKERS OF OVARIAN CANCER 
  Over the past decade, the power of high-throughput tech-
nologies has stimulated their use in many bio-medical appli-
cations. In this field, proteomics has become an important 
methodology in the biomarker identification. Using this 
method the expression of hundreds of proteins can be studied 
simultaneously, by taking advantage of their different bio-
chemical properties.  
  This approach has been applied to ovarian cancer leading 
to the identification of several differentially expressed pro-
teins related to platinum resistance. Among these, five pro-
teins annexin A3, destrin, cofilin 1, GSTO1-1 and IDHc 
showed the more appreciable results, confirmed also by 
quantitative PCR and western blot [71].  
  Proteomics studies have also been applied to tumor clas-
sification by using diseased tissues and serum specimens: 
Bengtsson  et al. used DIGE technology to distinguish be-
tween benign and malignant tumor groups leading to the 
identification of an heterogeneous groups of proteins in-
volved in several cellular processes [72].  
  By coupling laser capture microdissection and 2-DE, 
Brown Jones et al. revealed that the 52 KDa FK506 binding 
protein, RhoG-protein dissociation inhibitor and glyoxalase I 
were overexpressed in invasive ovarian cancer when com-
pared to low malignant potential ovarian tumors [73]. 
  The immune response to tumor associated antigens repre-
sents a possible serological tool for the diagnosis of cancer. 
Autoantibodies direct against tumor associated antigens pre-
sented by MHC I molecules have been identified by liquid 
chromatography - mass spectrometry/mass spectrometry 
(LC-MS/MS) using two human ovarian adenocarcinoma cell 
lines and serum sample from twenty patients, showing im-
portant implications in cancer detection and prognosis [74]. 
  Recently, emerging technologies are unravelling the 
plasma proteome.  
  Surface-enhanced laser desorption and ionization with 
time-of-flight spectrometry (SELDI-TOF) was employed for 
the rapid identification of serum proteins in ovarian cancer 
patients.  
  The strength of SELDI technology is based on the selec-
tive binding of proteins on a solid-phase protein chip surface 
where the sample is ionized by an energy laser impulse.  
  The protein profile of each specimen is then analyzed by 
software to discovery changes in the protein pattern. Petri-
coin  et al. analyzed the serum of unaffected controls and 
patients with ovarian cancers and were able to discriminate 
with a sensibility of 100% and a specificity of 94% all ovar-
ian cancers in the early stage [75].  
  Among the possible marker identified with SELDI there 
was the Haptoglobin, a glycoprotein secreted by liver cells 
and implicated in the metabolism of hemoglobulin. High 
levels of Hp- subunit were found serum of patients with 
ovarian cancer. The results of the ELISA test showed for 
Hp- a 64% sensitivity and 90% specificity alone and 91% 
sensitivity and 95% specificity if combined with CA125.  
  Expression levels of 169 proteins were studied by Mor et 
al. by antibody microarray in serum of 28 healthy women, 
18 women newly diagnosed with EOC and 40 women with 
recurrent disease.  
  This analysis led to the identification of four proteins: 
leptin, prolactin, osteopontin, and insulin-like growth factor-
II. Additional validation studies showed that the combination 
of the four proteins exhibited a sensitivity of 95%, a positive 
predictive value of 95%, a specificity of 95% and negative 
predictive value of 94% [76]. 
PROTEIN MARKERS IN BOT 
  An extensive analysis of the ovarian cellular pathways 
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ovarian surface epithelium (OSE), BOTs and high grade 
tumors. 
  A key feature is the modification in E-cadherin and N-
cadherin levels, integral membrane glycoproteins that medi-
ate calcium-dependent cell adhesions: a role for E-cadherin 
in the early events leading to cellular transformation has 
been proposed for two principal reasons.  
  The protein is expressed in inclusion cysts, in benign, 
borderline and malignant tumors of all stages but not in nor-
mal ovarian surface epithelium (OSE) [77].  
  Moreover, N-cadherin expression was detected in most 
benign and borderline tumors but was absent or heterogene-
ous in most carcinomas [78].  
  E-cadherin induces the activation of Akt and MAPK 
pathways and in this way increases proliferation and survival 
of ovarian cancer cells [79].  
  To corroborate these hypotheses, the expression of ex-
ogenous E-cadherin in mesenchymal IOSE-29 (immortal-
ized-OSE) has been associated with the development of 
ovarian cancer [80].  
  The role of E-cadherin in advanced tumor and metastasis 
is still debated and not strictly related to the aim of this re-
view. In general, the absence or the lower E-cadherin expres-
sion in ovarian cancers predicts poor patient survival when 
compared with ovarian tumors that express E-cadherin and 
correlates with high tumor grade and low overall survival 
rate [81]. 
  Transforming growth factor- (TGF- ) and epidermal 
growth factor (EGF) are known to promote EMT in ovarian 
cancer [82,83]. Smad3 is required to sustain TGF- induced 
EMT. Analysis of Smad3 expression in microarrays of se-
rous cystadenocarcinoma displayed lower levels of Smad3 
nuclear expression than benign and borderline tumors and a 
correlation with N-cadherin expression and poor survival 
[84].  
  Activin A (A), a member of the TGF-  family, was 
found to regulate the activation status of Akt and GSK. In 
ovarian cancer, A expression was elevated in stromal cells 
from carcinomas. Moreover, a different GSK- phosphoryla-
tion status was identified in benign cystadenomas, borderline 
tumors, and carcinomas [85]. 
  EMT can be induced by EGF through the activation of 
JAK2/STAT3 signaling pathway as demonstrated by Colom-
iere  et al. [86,87]. In patients, both phosphorylated JAK2 
and activated STAT3 showed higher expression in high 
grade tumors respect to normal ovaries and borderline tu-
mors [86]. The two cancer cell lines OVCA 433 and SKOV3 
treated with EGF down-regulated the expression of epithe-
lial-restricted E-cadherin and increased the expression of 
vimentin and 2,  6  1 integrin subunits [87]. EGF de-
creased also the expression of Neutrophil gelatinase-
associated lipocalin (NGAL) in the transition to mesenchy-
mal like cells. In vivo, NGAL was not expressed in normal 
tissues while both BOT and grade I tumors showed an in-
creased staining compared to grade 2 and 3 tumors [83].  
  Key cellular processes including adhesion and migration 
depend also largely on remodelling of cytoskeleton, a com-
plex network of molecules whose organization influences 
not only cellular shape but also the interaction between cells 
and the ECM microenvironment.  
  Both actins and microtubules have a role in these proc-
esses; however, ovarian cancer cell invasion and migration 
seemed to be principally affected targeting actin dynamics 
[88].  
  Actin is one of the most abundant intracellular proteins; it 
is represented by three distinct isoforms, ,  and .  and  
actin isoforms are expressed principally in non-muscle cells, 
 isoform in muscle cells. The organization of actin is driven 
by a plethora of proteins also known as Actin Binding Pro-
teins under the control of specific signaling pathways [89].  
  Disorganisation of actin cytoskeleton contributes to al-
terations in growth control and tumorigenesis [90].  
  Furthermore, actin remodelling is involved in lamellipo-
dia and pseudopodium formation during cancer cells inva-
sion and metastasis [91]. 
  The actin-binding protein Gelsolin regulates actin fila-
ments length and severing. It is downregulated in a large 
variety of human cancers including BOT and ovarian carci-
nomas [92]. Gelsolin showed suppressive activity in ovarian 
cancer cells growth and was correlated with tumor grade 
[93].  
  Fascin is implied in the organization of F-actin in parallel 
bundles (actin-structures with a role in cell architecture) and 
dynamic structures including filopodia and lamellipodia 
[94]. Fascin was not expressed in normal epithelial ovarian 
tissue [95], but up-regulated in cystadenomas, BOTs and 
carcinomas, suggesting that fascin may play an important 
role in tumor progression [96].  
  In addition, its stromal expression was significantly 
higher in malign epithelial ovarian tumors and BOT, com-
pared to normal ovaries and benign epithelial ovarian tumors 
[97]. 
  Also other cytoskeletal components, like intermediate 
filaments (IFs), have been reported to be involved in ovarian 
cancer. By two dimensional electrophoresis (2-DE) and mass 
spectrometry analysis, Bengtsson et al. identified several IFs 
differentially expressed in benign and malignant tumors 
when compared to BOTs. The proteins identified were 
Vimentin, Keratin I cytoskeletal 19 and Lamin A/C respec-
tively [98]. 
FUTURE PERSPECTIVES IN OVARIAN CANCER 
AND BOT DIAGNOSIS 
  High-throughput technologies have the potential to ad-
dress this task and in particular, recent advances in mass 
spectrometry imaging may stimulate new research in this 
area.  
  The direct analysis of ovarian cancer tissue sections by 
matrix-assisted laser desorption/ionization (MALDI) Imag-
ing led to the identification of an 11S proteasome fragment 
as an ovarian cancer marker with a different cellular localiza-
tion in benign and malign tissues [99].  
  So, MALDI-Imaging could bypass the limitations of 
many current technologies allowing the visualization of pro-246    Current Genomics, 2009, Vol. 10, No. 4  Tinelli et al. 
teins, peptides, lipids and small molecules directly on thin 
sections cut from fresh frozen or paraffin embedded tissues 
(FFPE) [100,101] without long and tedious steps of separa-
tion and extraction. 
  In our laboratory we are also exploring the possibility to 
probe mechanical properties of cancer cells by an atomic 
force microscopy (AFM) in order to obtain a nanomechani-
cal classification of BOTs. AFM is a versatile tool for imag-
ing and measuring the elastic properties of living and fixed 
cells [102].  
  The great advantage of AFM lies in the unique possibility 
to work with living cells in physiological conditions at   
37°C. Basically, cells seeded into Petri dishes are scanned by 
a tip, which is mounted to a cantilever spring to obtain a  
topographic image of the sample at high spatial resolution. 
CONCLUSION 
  Because of a lack of specific symptoms in the early phase 
and the limitations of existing markers for diagnostic meth-
ods, the ovarian cancer still represent, despite its low inci-
dence, one of the leading cause of death worldwide. The 
complete understanding of mechanisms controlling ovarian 
progression represents an important step toward the devel-
opment of a future appropriate therapy based on genomic 
and proteomics findings. Nevertheless, the study of low-
abundant proteins and the need to analyze a large body of 
sample to extrapolate significant results, make the pro-
teomics approach labour-intensive and the potential of a 
gene therapy for ovarian cancer, that involves blocking ex-
pression of specific ovarian oncogenes, seems to be far to be 
applied. Currently, many genomic tests used to diagnose 
ovarian cancer or guide its therapy do not decrease women's 
risk of dying from this disease or do not improve their qual-
ity of life (QoL). 
  Therefore, for their rapid investigations of biological 
specimens, mass spectrometry and protein arrays are evolv-
ing as alternative methodologies to the “classic proteomics 
approach” facilitating their use at many points of the disease 
management and the expanding our knowledge on biomark-
ers is likely to lead to more individualization of therapy and 
improvements in ovarian cancer prognosis. Several works 
has been published on observing the impact of this technol-
ogy in biomedical research [103]. We believe that the trans-
lation of all these information into the clinical practice could 
guide the development of appropriate targeted clinical ther-
apy, overtaking the current invasive surgical approach and 
avoiding the uncertainty of a long term clinical and instru-
mental follow up of a possible recurrence. 
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